TEVA Teva Pharmaceutical Industries
- 16.930
- +0.030+0.18%
- 16.990
- +0.060+0.35%
Teva Pharmaceutical Industries News
Teva Announced Saturday, Switching To UZEDY At Four Weeks After The Last Dose Of Once-monthly Paliperidone Palmitate Provided The Most Comparable Pharmacokinetic Profile Based On The Relevant PK Modeling Data For Schizophrenia
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA),today announced the presentation of seven studies from its long-acting injectable (LAI) schizophreni
Express News | Teva Presents First Real-World Data From the Impact-TD Registry Study at Psych Congress Elevate 2024
New Data Provide Schizophrenia Treatment Insights Into Switching to UZEDY (Risperidone) Extended-Release Injectable Suspension From Invega Sustenna (Paliperidone Palmitate)
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of seven studies from its long-acting injectable (LAI) schizophrenia research program.
Teva Presents First Real-World Data From the IMPACT-TD Registry Study at Psych Congress Elevate 2024
Nearly 98% of patients experience quality of life impact as a result of tardive dyskinesia (TD) including social, psychological, physical and recreational aspects of daily living Data highlight for
Express News | NYSE Order Imbalance 66872.0 Shares on Buy Side
Express News | NYSE Order Imbalance 129390.0 Shares on Buy Side
4 Analysts Assess Teva Pharmaceutical Indus: What You Need To Know
In the latest quarter, 4 analysts provided ratings for Teva Pharmaceutical Indus (NYSE:TEVA), showcasing a mix of bullish and bearish perspectives.The following table encapsulates their recent ratings
Teva Pharmaceuticals Is Maintained at Buy by B of A Securities
Teva Pharmaceuticals Is Maintained at Buy by B of A Securities
Teva Pharmaceutical Indus Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/30/2024 25.9% B of A Securities $18 → $21 Maintains Buy 05/13/2024 19.9% Piper Sandler $19 → $20 Reiter
Teva Wins FDA Nod for New Austedo Formulation
Express News | Teva : BofA Global Research Raises Price Objective to $21 From $18
Reported Earlier, Teva's AUSTEDO XR Receives FDA Green Light, One Pill, Once-Daily Dosage Now Available For TD And HD Chorea
U.S. FDA approves new one pill, once-daily AUSTEDO XR tablets (30, 36, 42, 48 mg/day)AUSTEDO XR offers more flexibility with the most once-daily doses of any vesicular monoamine transporter 2 (VMAT2)
Express News | NYSE Order Imbalance 117996.0 Shares on Sell Side
Teva Announces AUSTEDO XR (Deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 Mg/day)
U.S. FDA approves new one pill, once-daily AUSTEDO XR tablets (30, 36, 42, 48 mg/day) AUSTEDO XR offers more flexibility with the most once-daily doses of any vesicular monoamine transporter 2 (VMA
Press Release: Medincell: Update of the 2024 Financial Calendar
Medincell: Update of the 2024 Financial Calendar MONTPELLIER, France--(BUSINESS WIRE)--May 27, 2024-- Regulatory News: Medincell (Paris:MEDCL) announces an update to its 2024 financial agenda: Eve
Global Topical Wound Agents Market Size To Exceed USD 3.7 Billion By 2033 | CAGR Of 6.89%
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 28% Though Its Price And Business Still Lag The Industry
The Teva Pharmaceutical Industries Limited (NYSE:TEVA) share price has done very well over the last month, posting an excellent gain of 28%. The last month tops off a massive increase of 123% in th
Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $20
Barclays analyst Balaji Prasad maintains $Teva Pharmaceutical Industries(TEVA.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate o
Teva Pharmaceutical Industries Options Spot-On: On May 22nd, 93,565 Contracts Were Traded, With 880K Open Interest
On May 22nd ET, $Teva Pharmaceutical Industries(TEVA.US)$ had active options trading, with a total trading volume of 93,565 options for the day, of which put options accounted for 5.88% of the total t
Teva Pharmaceutical Indus's Options Frenzy: What You Need to Know
Investors with a lot of money to spend have taken a bearish stance on Teva Pharmaceutical Indus (NYSE:TEVA).And retail traders should know.We noticed this today when the positions showed up on publicl
Analysis
Price Target
No Data
